Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 16/20 | 0.58 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | CASP6 | P55212 | 1/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL449103 | 0.88 | AKR1B1 (0.50) | BACE1AKR1B1LMNAHPGDHTT | |
| SCHEMBL444740 | 0.80 | BACE1 (0.64) | BACE1 | |
| SCHEMBL430936 | 0.79 | BACE1 (0.63) | BACE1 | |
| SCHEMBL449885 | 0.78 | BACE1 (0.38) | BACE1AKR1B1LMNAHPGDHTT | |
| SCHEMBL430671 | 0.78 | BACE1 (0.38) | BACE1AKR1B1LMNAHPGDHTT | |
| SCHEMBL448629 | 0.73 | AKR1B1 (0.67) | AKR1B1 | |
| SCHEMBL445942 | 0.73 | BACE1 (0.48) | BACE1 | |
| SCHEMBL445570 | 0.72 | BACE1 (0.37) | BACE1 | |
| SCHEMBL24699359 | 0.71 | BACE1 (0.48) | BACE1AKR1B1LMNAHPGDHTT | |
| SCHEMBL30016504 | 0.71 | BACE1 (0.48) | BACE1AKR1B1LMNAHPGDHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. | 2012-03-15 | — | — | US | disclosed |
| WO-2011123674-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | ARRAY BIOPHARMA INC. (US) | 2011-10-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065195-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | APP, BACE1, PSEN1 | BACE1 2/4885AKR1B1 112/4885LMNA 463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.